Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04452721
Recruiting Observational

Prognosis Factors for the Treatment of Pectus Carinatum With a Dynamic Compression System

NCT04452721 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Observational
Started
2020-07-07
Last updated
2025-01-29

Condition(s) studied

Pectus Carinatum

Investigational drug(s) / intervention(s)

dynamic compression system

dynamic compression system: It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it

Study summary

Pectus carinatum is a deformation of the thoracic wall causing an aesthetic prejudice. Since 2011, our team uses a dynamic compression system to treat this deformation. It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it. The local cohort is one of the largest in the world. The few previous publications have shown the validity of this method, but the prognosis factors for success of this innovative treatment are not yet identified.

Eligibility

Sex
ALL
Min age
6 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Patient who received proper information about the study. * Patient with clinically diagnosed pectus carinatum. * Treated at Saint-Etienne University Hospital using a dynamic compression system. * Between October 2011 and January 2020 for the retrospective part, then between January 2020 and January 2022 for the validation cohort. * With more than 6 months of follow-up since the beginning of the treatment. Exclusion Criteria: \-

Primary outcome measure(s)

  • Decrease of the deformation of more than 50% (measured in mm) after 6 months of treatment — After 6 months of treatment
    Dynamic compression system

Trial sites (1)

FacilityCityRegionStatus
CHU de Saint-Etienne Saint-Etienne France Recruiting

More Centre Hospitalier Universitaire de Saint Etienne trials in France

Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia. Recruiting
Impact of Fatty Stimuli on Cerebral Activity in Anorexia Nervosa: a Multi-sensory Approach Starting soon
Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses Active, not recruiting
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells Recruiting
Hysterectomy by Transvaginal Natural Orifice Transluminal Endoscopic Surgery Versus or Laparoscopic Hysterectomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04452721 on ClinicalTrials.gov ↗ ← All trials in France